[ET Net News Agency, 3 July 2020] Frontage Holdings Corporation (01521) said its
subsidiary Frontage Labs has agreed to buy 100% of the equity interest in Acme Bioscience,
Inc. (the target) for a cash consideration of up to USD26 million.
The target is a corporation incorporated under the laws of Delaware, U.S. It provides
synthetic & medicinal chemistry and process research & development services for
biopharmaceutical companies specializing in drug discovery and development. (RC)